top of page
  • Recruiting

NCT05113342: Phase 1/2: Descartes-25 in Relapsed/Refractory Multiple Myeloma

Updated: Jun 22, 2022

NCT05113342: Phase 1/2: Descartes-25 in Relapsed/Refractory Multiple Myeloma


descartes 25 cartesian therapeutics

Descartes-25 in Relapsed/Refractory Multiple Myeloma


This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.


Sponsor

Cartesian Therapeutics

 

ClinicalTrials.gov Identifier: NCT05113342


Official Title: Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma


First Posted: November 9, 2021


Click here to see details on ClinicalTrials.gov